NRX Pharmaceuticals, Inc. Income Statement
NRXP|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
NRX Pharmaceuticals, Inc. reported $0 in revenue and $25M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -5.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | - |
| SG&A Expense | $13.5M | $14.2M |
| R&D Expense | $6.2M | $13.4M |
| Operating Income | -$18.5M | -$27.8M |
| Income Tax | $0 | $0 |
| Net Income | -$25.1M | -$30.1M |
| EPS (Basic) | -$2.36 | -$3.98 |
| Shares Outstanding | 14.6M | 8.4M |